CRTH2 Antagonist Programme

Oxagen has identified a number of potent antagonists of the CRTH2 receptor which are highly selective small molecular weight compounds with a range of physical properties enabling multiple administration routes to treat a range of allergic and inflammatory diseases in man. Preclinical and clinical activity has been demonstrated in a number of models of asthma, allergic and inflammatory diseases.

The lead molecule OC000459 has successfully completed Phase II clinical proof-of-concept studies in multiple allergic/inflammatory disease settings as well as a Phase IIb asthma clinical study. OC000459 is covered by granted patents in major markets and, together with other molecules in this and other series, all covered by Oxagen’s patent estate, is being developed for a range of allergic and inflammatory conditions.

OC000459 has demonstrated an excellent safety profile in over 800 subjects and has shown efficacy in asthma, allergic rhinitis and allergic conjunctivitis and a reduction in eosinophil infiltration in eosinophilic esophagitis. The company recently published data from its successful Phase IIa asthma study of OC000459 in Barnes et al (2011). In asthmatics OC000459 has shown positive impacts on lung function, symptoms, quality-of-life, exacerbations and respiratory tract infections with selected data being shown in the company fact sheet.

Please click here for the company factsheet